|Day's Range||11.640 - 11.960|
|52 Week Range||6.470 - 12.220|
|PE Ratio (TTM)||33.93|
|Dividend & Yield||0.02 (1.08%)|
|1y Target Est||N/A|
Shares of CSPC Pharmaceutical Group (1093.HK) have rallied 35% over the past year but there could room for further upside. Jefferies analyst Eugene Huang initiated coverage of the Hong Kong-based drug maker today with a buy rating and a HKD13 a share target price, which implies 31% upside. CSPC is one of the first Chinese pharma leaders to transform from an API producer to a new drug innovator, and is well placed to reap the benefits.
CSPC Pharmaceutical (CHPTY) can be an exciting pick in the market as the firm saw robust EPS growth last year, and is looking great for this year too.
One company that might be well-positioned for future earnings growth is CSPC Pharmaceutical Group Limited (CHPTY)